The Enduring Success of Hybridoma-based Antibody Development
White Paper Aug 14, 2019
Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.
Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.
Download these whitepapers to explore:
- The key benefits of using hybridoma-based antibody development
- Perceived misconceptions relating to hybridoma technology
- Alternative approaches that currently exist for mAb generation
Related White Papers
One of the common molecular analyses is the determination of a lead molecule’s binding kinetics and affinity to the target. This warrants the need for analytical instruments capable of characterizing such molecules. Download this whitepaper to discover an approach that accurately measures multiple high-affinity interactions over long run times.READ MORE
Preventive measures, accurate disease diagnostics and effective contact tracing are still considered fundamental in efforts to combat the SARS-CoV-2 pandemic. Download this whitepaper to discover serological testing methods, antigen testing methods and the impact of COVID-19 variants and antibody cross reactivity.READ MORE
Data accessibility has been a challenge because the lab operator’s relationship to data is usually prescribed by preset LIMS features. Using data science algorithms, it is now possible to process and integrate all LIMS and enterprise data to provide valuable insights and timely, meaningful recommendations. Access this whitepaper to discover a technology that provides a holistic view of your data, delivers statistical and business analysis and increases productivity.